Kết quả đóng ống động mạch bằng dụng cụ Amplatzer tại Bệnh viện Nhi Thái Bình

Patent Ductus Arteriosus (PDA) remains a prevalent congenital heart defect, often leading to significant cardiovascular complications if left uncorrected. While it typically closes spontaneously shortly after birth, its persistence necessitates intervention to prevent issues such as pulmonary hypertension, heart failure, and recurrent infections. Historically, surgical ligation was the primary treatment, but the advent of transcatheter device closure, particularly with the Amplatzer device, has revolutionized management, offering a less invasive and highly effective alternative. This study evaluates the initial outcomes of transcatheter PDA closure using the Amplatzer device at Thai Binh Pediatric Hospital from 2021 to 2025, aiming to establish the feasibility and efficacy of this advanced interventional cardiology technique in a provincial healthcare setting.

Pediatric cardiologists, interventional cardiologists, general pediatricians, and healthcare administrators in provincial hospitals.

This study investigated the effectiveness and safety of patent ductus arteriosus (PDA) closure using the Amplatzer device at Thai Binh Pediatric Hospital between 2021 and 2025. Conducted as a descriptive longitudinal study, the research involved 31 pediatric patients diagnosed with congenital PDA who underwent transcatheter intervention. Baseline characteristics and post-intervention outcomes were meticulously compared to assess the procedure's success, identify any complications, and evaluate changes in cardiac parameters. The findings demonstrate a remarkable success rate of 93.5% for Amplatzer device closure. Patient demographics revealed a median age of 19 months, with a female-to-male ratio of 1.58:1 and an average weight of 10.53 kg, indicating the procedure's applicability even in younger and smaller children. While 6.5% of cases required surgical conversion due to complex anatomies or large shunts, complications were generally infrequent and non-life-threatening. The most common minor complication observed was hematoma at the puncture site (45.2%), which was effectively managed with antibiotics, highlighting the learning curve associated with a new technique. Notably, all residual shunts resolved within one month post-intervention, and a significant reduction in left cardiac chamber dilation was observed, indicating substantial clinical improvement. This successful implementation at a provincial hospital underscores the value of minimally invasive treatments for congenital heart defects, reducing the burden of open-heart surgery and the need for referrals to central facilities. The study concludes that Amplatzer device closure is a safe, highly effective, and feasible option, expanding access to advanced pediatric cardiology interventions.